The present invention relates to a method for the production of a first binding domain capable of binding to an epitope of a human CD3 (epsilon) epsilon chain and a non-chimpanzee primate CD3 epsilon chain and a second binding domain capable of binding to a prostate stem cell antigen (PSCA), a B-lymphocyte antigen CD19 EGF-like domain 1 of EpCAM, fibroblast activation protein alpha (FAPa) and insulin-like growth factor I receptor (IGF-IR or EGFR) encoded by the factor receptor (c-MET), endosialin, IGF-1R), wherein the epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6 and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of SEQ ID NOS: Lt; RTI ID = 0.0 monoclonal / RTI antibody molecule. The present invention also provides a vector, a host, and a method for producing the bispecific antibody molecule as well as a nucleic acid encoding the bispecific antibody molecule. In addition, the present invention relates to pharmaceutical compositions comprising said bispecific antibody molecules and pharmaceutical uses of said bispecific antibody molecules.
展开▼
机译：本发明涉及用于产生能够结合人CD3（ε）ε链的表位和非黑猩猩灵长类CD3ε链的第一结合域和能够结合前列腺的第二结合域的方法。干细胞抗原（PSCA），EpCAM的B淋巴细胞抗原CD19 EGF样结构域1，成纤维细胞活化蛋白α（FAPa）和由因子受体（c编码的胰岛素样生长因子I受体（IGF-IR或EGFR） -MET），内皮唾液酸蛋白，IGF-1R），其中该表位包含选自SEQ ID NOS：2、4、6和8的氨基酸序列，以及能够结合选自以下的抗原的第二结合结构域SEQ ID NOS：Lt;单克隆抗体分子。本发明还提供了用于产生双特异性抗体分子的载体，宿主和方法，以及编码双特异性抗体分子的核酸。另外，本发明涉及包含所述双特异性抗体分子的药物组合物和所述双特异性抗体分子的药物用途。
展开▼
